IngredientsRauwolscine, also known as isoyohimbine, α-yohimbine, and corynanthidine, is an alkaloid found in various species within the genera Rauvolfia and Corynanthe (including Pausinystalia). On dietary supplement labels, rauwolscine is sometimes listed as alpha-yohimbine or α-yohimbine. The compound also carries the systematic IUPAC-related name 17α-hydroxy-20α-yohimban-16β-carboxylic acid methyl ester.
Rauwolscine is an indole alkaloid and an alpha-2 adrenoceptor antagonist. Rauwolscine is a stereoisomer of yohimbine — it is chemically identical but differs in its three-dimensional orientation. α-Yohimbine (17α-hydroxy-20α-yohimban-16β-carboxylic acid methyl ester), or rauwolscine, is one of the three diastereoisomers of yohimbine (17α-hydroxy-20β-yohimban-16α-carboxylic acid methyl ester); the other two isomers are corynanthine and 3-epi-alpha-yohimbine. Alpha-yohimbine has the same molecular formula and molecular weight as yohimbine: C₂₁H₂₆N₂O₃, with a molecular weight of 354.44 g/mol. Owing to differences in the spatial arrangement of atoms, however, its properties are different.
Rauwolscine is found in numerous botanical sources and can be extracted from the bark of the Pausinystalia yohimbe tree and from the Rauwolfia root. A specific extraction process has been described for obtaining alpha-yohimbine in high yields from Rauwolfia species, particularly from the leaves of Rauwolfia canescens. The extraction process is equally applicable to bark, stem, roots, and other parts, and from any species of Rauwolfia, being a general chemical process for the specific extraction of alpha-yohimbine in high quantities and in highly purified form.
The genus Rauwolfia encompasses a group of plants that contain more than 30 chemical compounds, including the stimulants rauwolscine and yohimbine, as well as reserpine, which can be used as a drug. Rauwolscine is an indole alkaloid with stimulant, aphrodisiac, and local anesthetic effects found naturally in plants of the genera Rauwolfia and Pausinystalia, along with several other active alkaloids including yohimbine.
Rauwolscine is one of the many chemicals occurring in Rauwolfia plants; it can be extracted from these plants, but it can also be created in a laboratory. In the commercial ingredient market, rauwolscine is most often supplied as a high-purity standardized material, with 98% rauwolscine (HPLC) being the most common specification. It is typically available in small-dose raw material formats suitable for precise formulation, reflecting its potency and targeted use in finished dietary supplement products. The compound appears on labels of dietary supplement products most likely for pre-workout, weight loss, brain health, or other performance-enhancement purposes.
Rauwolfia serpentina, native to the Indian subcontinent and Southeast Asia, has been used for centuries in traditional medicine systems of Ayurveda and Unani. Sarpagandha root powder has been used as a traditional medicine in India for over 2,500 years. Rauvolfia serpentina has been recorded in Ayurvedic texts for well over two millennia; the Caraka Samhita (c. 300 CE) mentions a plant called "Sarpa Gandha" used for pacifying aggravated Vata dosha and stabilizing Prana, hinting already at its calming potential. The Sushruta Samhita alludes to snakeroot's efficacy in managing what ancient physicians termed "Unmada" (psychosis) and "Hridroga" (heart disorders).
In Ayurvedic medicine, Sarpagandha is classified as a medhya rasayana, or mind rejuvenator. Extracts of different parts and of plants resembling Rauwolfia were used in Hindu medicine for snakebite, insomnia, insanity, and many other diseases. The plant is known in the Indian tradition by a number of vernacular names. The plant is also known as Snakeroot, Sarpagandha, Chandrabagha, Chotachand, Chandrika, and Harkaya.
The roots, leaves, and extracted juice are of medicinal importance as they contain many metabolites, particularly unique alkaloids; various parts of this plant have been used in traditional medicine (Ayurvedic medicine) for centuries to treat a variety of ailments including snake bites, fever, general weakness, insomnia, intestinal diseases, liver problems, vertigo, and even mental illness. Traditional preparations often involve powdering the dried roots and mixing them with honey or ghee.
In the Siddha system of medicine, R. serpentina roots are also used to treat hypertension-associated cerebral pain, dizziness, amenorrhea, and oligomenorrhea. In the Unani system, R. serpentina is used as a nervine tonic (Musakkin-e-Asab), sedative, and hypnotic (Musakkin-wo-Munawwim).
It is important to note that the traditional uses documented above pertain to whole-plant preparations of Rauwolfia serpentina — preparations that contain dozens of alkaloids beyond rauwolscine alone, most notably reserpine. Traditional Ayurvedic practice harnesses the plant's dried roots and rhizomes, which are rich in indole alkaloids like reserpine, ajmaline, ajmalicine, and serpentine. The historical record of traditional use therefore reflects the action of these complex mixtures and cannot be attributed exclusively to rauwolscine.
This small shrub, native to the Orient from India to Sumatra, has for centuries been used in Indian medicine. In 1952, reserpine, one of several alkaloids in the plant, was isolated from its root and has since been evaluated in Western medicine as one of the most valuable drugs for treating high blood pressure. The transition from traditional use to modern medicine exemplifies reverse pharmacology, where empirical observations guide drug discovery. Modern research has validated claims regarding the plant's sedative, antipsychotic, and gastrointestinal benefits, while advanced techniques have allowed the refinement of its therapeutic applications.
The therapeutic properties of Rauwolfia serpentina are associated with the presence of various phytochemical compounds such as alkaloids, phenols/polyphenols, saponins, tannins, yohimbine, and reserpine. Rauwolscine itself is one member of this broader alkaloid suite. Yohimbe bark extract generally contains low concentrations of yohimbine — approximately 6% total indole alkaloids, of which only 10–15% is yohimbine — making it difficult to standardize commercial preparations to specific alkaloid contents.
Rauwolscine and its isomers, yohimbine and corynanthine, differ little in their physical properties or effects on serotonin and dopamine receptors; however, the three isomers do differ significantly in their affinity for the alpha-1 and alpha-2 adrenoceptor subtypes. Rauwolscine is more selective for alpha-2 adrenoceptors than yohimbine, making it a valuable tool for differentiating alpha-1 and alpha-2 adrenergic receptors in neurological research.
Rauwolscine acts predominantly as an α₂-adrenergic receptor antagonist. Rauwolscine is a pharmacological agent classified as a selective alpha-2 adrenergic receptor antagonist. It has been widely used in neuropharmacological research to investigate the role of alpha-2 adrenergic receptors in the nervous system. Rauwolscine acts as a competitive antagonist at alpha-2 adrenergic receptors, as demonstrated by Schild analysis. Increasing concentrations of rauwolscine cause a rightward shift in norepinephrine dose-response curves without altering the slope or range of responsiveness, indicating competitive antagonism.
Alpha-2 adrenergic receptors mediate presynaptic inhibition of norepinephrine release and postsynaptic modulation of neuronal activity. Rauwolscine's blockade of these receptors results in increased norepinephrine release, as shown in studies using guinea pig hippocampus and mouse brain.
Rauwolscine exhibits selectivity particularly for the alpha-2C adrenergic receptor subtype. [³H]Rauwolscine is routinely used as a radioligand for labeling alpha-2 adrenoceptors and has some selectivity for the alpha-2C over the other alpha-2 receptor subtypes.
By blocking these inhibitory receptors, rauwolscine prevents the normal negative feedback mechanisms that limit norepinephrine release, resulting in sustained sympathetic activation and enhanced metabolic rate. This mechanism is particularly significant for fat loss applications, as alpha-2 receptors are densely concentrated in adipose tissue where they typically inhibit lipolysis.
Yohimbine HCl is a non-selective alpha-antagonist that blocks both alpha-2 and, to a significant degree, alpha-1 adrenergic receptors. Blocking alpha-1 receptors contributes to its pronounced peripheral and central stimulant effects, including increased heart rate, blood pressure, and anxiety. Rauwolscine is reported to exhibit greater selectivity for alpha-2 receptors over alpha-1 receptors. This higher selectivity means it may more specifically target the lipolysis-inhibiting receptors on fat cells while having a lesser direct impact on receptors that drive strong cardiovascular and anxiety responses.
Rauwolscine has also been shown to function as a 5-HT1A receptor partial agonist and a 5-HT2A and 5-HT2B receptor antagonist.
5-HT1A: The alpha-2 adrenergic antagonist [³H]rauwolscine binds with comparable nanomolar affinity to alpha-2 adrenoceptors and the nonadrenergic 5-HT1A receptor sites in human frontal cortex membranes. This suggests that [³H]rauwolscine is a 5-HT1A receptor agonist; this conclusion is compatible with earlier functional studies indicating that rauwolscine (as well as yohimbine) has agonistic properties at the level of 5-HT autoreceptors. A subsequent study using recombinant human receptors confirmed this: rauwolscine and yohimbine are partial agonists for the human 5-HT1A receptor. Specifically, for rauwolscine, the IC₅₀ was 1.5 ± 0.2 µM for inhibition of adenylyl cyclase, with an activity ratio of 0.70 compared to the full agonist serotonin.
5-HT2B: When using [³H]5-HT as a radioligand, rauwolscine was determined to have relatively high affinity for the human 5-HT2B receptor (Ki human = 14.3 ± 1.2 nM). These studies were performed to characterize [³H]rauwolscine as a radioligand for the cloned human 5-HT2B receptor. These studies display the usefulness of [³H]rauwolscine as an antagonist radioligand for the cloned human 5-HT2B receptor and provide a good tool for the study of both the agonist high- and low-affinity states of the human cloned 5-HT2B receptor.
Alpha-1 adrenoceptors are selectively stimulated by phenylephrine and blocked by prazosin, whereas alpha-2 adrenoceptors are selectively stimulated by guanabenz and blocked by rauwolscine. Until recently, rauwolscine and yohimbine were considered the best preferential alpha-2 adrenoceptor antagonists available for experimental and pharmacological studies. Although [³H]idazoxan labeling appears over brain regions receiving noradrenergic innervation, [³H]rauwolscine binding sites are localized most densely in several areas corresponding to dopaminergic terminal fields.
Proposed Mechanism: Like yohimbine, rauwolscine may increase fat burning by blocking alpha-2 receptors. Both probably work by activating the fight-or-flight system, which mobilizes fats from stores and uses them for energy.
Animal Evidence: In a study where the alpha-2 receptor blockers yohimbine and rauwolscine were administered to food-restricted obese (ob/ob) and lean mice, both compounds significantly reduced the 3- and 6-hour food intake. The obese mice were, however, more sensitive to this anorectic effect than lean mice. Obese and lean mice given rauwolscine consumed up to 33% less food than mice who did not receive it. Rauwolscine achieved the same effect as yohimbine at one-third the dose.
Human Evidence: Current research on rauwolscine remains primarily limited to animal studies and in vitro investigations, with comprehensive human clinical trials still needed to establish definitive safety and efficacy profiles. There are no high-quality human trials on rauwolscine itself, and much of what is claimed is borrowed from research on yohimbine or from laboratory receptor studies rather than direct clinical data.
Evidence Strength: Preliminary. The mechanistic rationale is plausible and supported by animal and receptor-binding data, but direct fat-loss effects in humans remain undemonstrated.
Animal Evidence: Rauwolscine's fat-reducing effects are not direct but work indirectly through appetite suppression and enhanced sympathetic nervous system activity, as demonstrated in the Callahan et al. (1984) study showing a 33% food intake reduction in mice. Effective anorectic doses of yohimbine did not affect water intake in water-deprived lean mice, suggesting a specific effect of the drug upon food intake.
Evidence Strength: Animal data only. No controlled human trials have specifically examined rauwolscine's appetite-suppressing effects.
Rauwolscine is described as a central nervous system stimulant, a local anesthetic, and a vague aphrodisiac. The compound also shows promise for supporting healthy sexual function through vascular and neurological pathways, similar to its structural analog yohimbine. Rauwolscine blocks alpha-2 adrenergic receptors, which may support sexual function but have mixed effects on heart health and anxiety. Its effects on sexual function are similar to yohimbine's; however, its effects in humans are unknown, as current research is limited to animals.
Evidence Strength: Speculative, based largely on mechanistic analogy to yohimbine and animal data. No dedicated human clinical trials exist.
In an animal study, rauwolscine reduced anxiety in rats to the same degree as the anti-anxiety drug diazepam (Valium), whereas yohimbine had no effect on anxiety in this study. However, rauwolscine is a double-edged sword when it comes to anxiety, as it might also amplify the stress response. The partial agonism at 5-HT1A receptors, documented in receptor-binding studies, may explain the anxiolytic signal seen in animal models.
Evidence Strength: Animal and receptor-binding data only. The anxiety effects appear potentially bidirectional; no controlled human studies have examined mood or anxiety outcomes.
The enhanced selectivity of rauwolscine for alpha-2 adrenoceptors has made it particularly useful in neuroscience research for understanding the specific roles of different adrenergic receptor subtypes in brain function and neuroprotection. Dysregulation of locus coeruleus–noradrenergic neurotransmission may contribute to cognitive and/or arousal dysfunction associated with a variety of psychiatric disorders, including ADHD, sleep and arousal disorders, and certain affective disorders, including PTSD. The locus coeruleus–noradrenergic system represents an appropriate target for pharmacological treatment of specific attention, memory, and/or arousal dysfunction. Rauwolscine is used as a research tool in these investigations but has not itself been evaluated in clinical trials for these conditions.
There is not enough reliable information to know what an appropriate dose of rauwolscine might be. The following dosage information is drawn from what has been observed in available sources:
Due to rauwolscine's higher potency at alpha-2 receptors, lower doses are typically used compared to yohimbine.
Rauwolscine is similar to yohimbine but has yet to be tested in humans, so its exact effects are unknown. Clinical trials are needed to confirm the benefits seen in animal and cell research and to determine the safety, absorption, and appropriate dosage of rauwolscine. The safety profile of rauwolscine is relatively unknown, given the lack of well-designed clinical studies.
Both rauwolscine and yohimbine carry similar cardiovascular and neurological risks due to their shared alpha-2 adrenergic receptor antagonist properties. They have been associated with severe adverse events and may harm health when used inappropriately. Yohimbine has a more extensive safety database due to its longer history of clinical use and research, while the lack of comprehensive human safety data for rauwolscine makes risk assessment challenging.
The side effect profile of rauwolscine closely mirrors that of yohimbine due to their shared mechanisms of action. Common side effects include cardiovascular effects (lowered blood pressure, slowed heart rate, arrhythmias), neurological effects (anxiety, restlessness, insomnia), and gastrointestinal effects (nausea, vomiting, diarrhea). Additional reported effects include headaches, dry mouth, and tremors in some users.
The side effects of rauwolscine at high doses include hypertension, tachycardia, agitation, hypervigilance, anxiety, tremors, nausea, and urinary frequency, with more severe adverse events potentially including moderate to severe cardiac effects.
Excessive intake may lead to severe sympathomimetic effects including rapid heart rate, hypertension, anxiety, tremors, and potentially dangerous cardiovascular events. There is no specific antidote, and treatment is typically supportive.
Specific populations should avoid this compound, including pregnant and breastfeeding women, individuals with anxiety disorders, bleeding conditions, heart disease, PTSD, or schizophrenia.
Rauwolscine is not the same as yohimbine, but the two are very similar, and both are stimulants. Neither Rauwolfia nor rauwolscine is prohibited for use by U.S. Military Service Members, and neither should cause a positive result on a military drug test.
Rauwolscine has been found in fat-burning and workout dietary supplements in Canada that were recalled due to safety concerns. The alkaloid concentrations in whole plant materials are highly variable and unpredictable, making standardized extracts necessary for consistent research applications. Traditional preparation methods do not guarantee specific alkaloid content.
The limited scientific evidence available suggests a need for further research to better understand the efficacy, safety, and potential health benefits of rauwolscine.
Health conditions that Rauwolscine may help support.
Rauwolscine is an alpha-2 adrenergic receptor antagonist (diastereomer of yohimbine) from Rauwolfia and Pausinystalia species that promotes fat mobilization and thermogenesis through the same mechanism as yohimbine. It has greater alpha-2 receptor selectivity and potency than yohimbine. It is recognized in the thermogenic supplement literature for its adrenergic fat-mobilizing effects.
Body systems that Rauwolscine may help support.
Go back